Casey M Rebholz1, Morgan E Grams2, Kunihiro Matsushita3, Elizabeth Selvin4, Josef Coresh4. 1. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: crebhol1@jhu.edu. 2. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD. 3. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: Atherosclerosis Risk in Communities (ARIC) Study participants from 4 US communities. PREDICTORS: Percent change in levels of filtration markers (eGFRcr, cystatin C-based eGFR [eGFRcys], the inverse of β2-microglobulin concentration [1/B2M]) over a 6-year period. OUTCOME: Incident ESRD. MEASUREMENTS: Cox proportional hazards regression with adjustment for demographics, kidney disease risk factors, and first measurement of eGFRcr. RESULTS: During a median follow-up of 13 years, there were 142 incident ESRD cases. In adjusted analysis, declines > 30% in eGFRcr, eGFRcys, and 1/B2M were associated significantly with ESRD compared with stable concentrations of filtration markers (HRs of 19.96 [95% CI, 11.73-33.96], 16.67 [95% CI, 10.27-27.06], and 22.53 [95% CI, 13.20-38.43], respectively). Using the average of declines in the 3 markers, >30% decline conferred higher ESRD risk than that for eGFRcr alone (HR, 31.97 [95% CI, 19.40-52.70; P=0.03] vs eGFRcr). LIMITATIONS: Measurement error could influence estimation of change in filtration marker levels. CONCLUSIONS: A >30% decline in kidney function assessed using novel filtration markers is associated strongly with ESRD, suggesting the potential utility of measuring change in cystatin C and B2M levels in settings in which improved outcome ascertainment is needed, such as clinical trials.
BACKGROUND:Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: Atherosclerosis Risk in Communities (ARIC) Study participants from 4 US communities. PREDICTORS: Percent change in levels of filtration markers (eGFRcr, cystatin C-based eGFR [eGFRcys], the inverse of β2-microglobulin concentration [1/B2M]) over a 6-year period. OUTCOME: Incident ESRD. MEASUREMENTS: Cox proportional hazards regression with adjustment for demographics, kidney disease risk factors, and first measurement of eGFRcr. RESULTS: During a median follow-up of 13 years, there were 142 incident ESRD cases. In adjusted analysis, declines > 30% in eGFRcr, eGFRcys, and 1/B2M were associated significantly with ESRD compared with stable concentrations of filtration markers (HRs of 19.96 [95% CI, 11.73-33.96], 16.67 [95% CI, 10.27-27.06], and 22.53 [95% CI, 13.20-38.43], respectively). Using the average of declines in the 3 markers, >30% decline conferred higher ESRD risk than that for eGFRcr alone (HR, 31.97 [95% CI, 19.40-52.70; P=0.03] vs eGFRcr). LIMITATIONS: Measurement error could influence estimation of change in filtration marker levels. CONCLUSIONS: A >30% decline in kidney function assessed using novel filtration markers is associated strongly with ESRD, suggesting the potential utility of measuring change in cystatin C and B2M levels in settings in which improved outcome ascertainment is needed, such as clinical trials.
Authors: Tanvir Chowdhury Turin; Josef Coresh; Marcello Tonelli; Paul E Stevens; Paul E de Jong; Christopher K T Farmer; Kunihiro Matsushita; Brenda R Hemmelgarn Journal: Nephrol Dial Transplant Date: 2012-07-03 Impact factor: 5.992
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Christina M Parrinello; Morgan E Grams; David Couper; Christie M Ballantyne; Ron C Hoogeveen; John H Eckfeldt; Elizabeth Selvin; Josef Coresh Journal: Clin Chem Date: 2015-05-07 Impact factor: 8.327
Authors: Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Zeno Stanga; Stefan Nock; Pedro Medina-Escobar; Urs E Nydegger; Martin Risch; Lorenz Risch Journal: PLoS One Date: 2013-08-22 Impact factor: 3.240
Authors: Josef Coresh; Tanvir Chowdhury Turin; Ron T Gansevoort; Andrew S Levey; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Lawrence J Appel; Hisatomi Arima; Steven J Chadban; Massimo Cirillo; Ognjenka Djurdjev; Jamie A Green; Gunnar H Heine; Lesley A Inker; Fujiko Irie; Areef Ishani; Joachim H Ix; Csaba P Kovesdy; Angharad Marks; Takayoshi Ohkubo; Varda Shalev; Anoop Shankar; Chi Pang Wen; Paul E de Jong; Kunitoshi Iseki; Benedicte Stengel Journal: JAMA Date: 2014-06-25 Impact factor: 56.272
Authors: C M Parrinello; K Matsushita; M Woodward; L E Wagenknecht; J Coresh; E Selvin Journal: Diabetes Obes Metab Date: 2016-06-14 Impact factor: 6.577
Authors: Anna E Prizment; Amy M Linabery; Pamela L Lutsey; Elizabeth Selvin; Heather H Nelson; Aaron R Folsom; Timothy R Church; Charles G Drake; Elizabeth A Platz; Corinne Joshu Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02-05 Impact factor: 4.254
Authors: Casey M Rebholz; Morgan E Grams; Kunihiro Matsushita; Lesley A Inker; Meredith C Foster; Andrew S Levey; Elizabeth Selvin; Josef Coresh Journal: Clin J Am Soc Nephrol Date: 2015-03-30 Impact factor: 8.237
Authors: Casey M Rebholz; Morgan E Grams; Yuan Chen; Alden L Gross; Yingying Sang; Josef Coresh; Elizabeth Selvin Journal: Am J Epidemiol Date: 2017-10-15 Impact factor: 4.897
Authors: Casey M Rebholz; Lesley A Inker; Yuan Chen; Menglu Liang; Meredith C Foster; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Mark J Sarnak; Chi-Yuan Hsu; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2017-06-23 Impact factor: 8.860
Authors: Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Shelley Hurwitz; Chi-Yuan Hsu; Harold I Feldman; Dawei Xie; Kathleen D Liu; Theodore E Mifflin; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Joseph V Bonventre; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2018-07-18 Impact factor: 8.860
Authors: Louise J Maple-Brown; Jaquelyne T Hughes; Rebecca Ritte; Federica Barzi; Wendy E Hoy; Paul D Lawton; Graham R D Jones; Elizabeth Death; Alison Simmonds; Ashim K Sinha; Sajiv Cherian; Mark A B Thomas; Robyn McDermott; Alex D H Brown; Kerin O'Dea; George Jerums; Alan Cass; Richard J MacIsaac Journal: Clin J Am Soc Nephrol Date: 2016-04-13 Impact factor: 8.237